drugset / Trial / NCT02641457
Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
NaSingle-groupOpen-labelTreatment
Summary
Aflibercept (Eylea®) and ranibizumab (Lucentis®) are an anti-VEGF, but there are differences between the two drugs. To determine and compare whether intraocular aflibercept and ranibizumab decreases rubeosis iridis (RI) in patients with neovascular glaucoma (NVG).
Timeline
- Start
- 2014-03
- Primary completion
- 2015-03
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 2 mg | Intravitreal |
| Subject | Ranibizumab | Monoclonal antibody | 1.25 mg | Intravitreal |